Isoflurophate

CHEMBL1025 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
184.2 g/mol
LogP
1.2
Phase
4

This irreversible cholinesterase inhibitor works by permanently blocking the enzyme that breaks down acetylcholine, causing prolonged nerve stimulation; it was used historically as long-acting eye drops to treat glaucoma and certain forms of crossed eyes. Due to its toxicity and the availability of safer alternatives, its medical use has become very limited.

Molekularmasse

184,1500 g/mol

LogP

1,20

TPSA

35,50 Ų

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Wirkmechanismus

Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)OP(=O)(F)OC(C)C

InChI

InChI=1S/C6H14FO3P/c1-5(2)9-11(7,8)10-6(3)4/h5-6H,1-4H3

Molecular Formula

C6H14FO3P

HBD / HBA

- / 4

Rotierbare Bindungen

4

Schwere Atome

11

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

This irreversible cholinesterase inhibitor works by permanently blocking the enzyme that breaks down acetylcholine, causing prolonged nerve stimulation; it was used historically as long-acting eye drops to treat glaucoma and certain forms of crossed eyes. Due to its toxicity and the availability of safer alternatives, its medical use has become very limited.

Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.

Yes, Isoflurophate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1025. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5936. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.